Are GLP-1 Agonists New, and What Does the Safety Record Show?

How Old Is the GLP-1 Drug Class?

GLP-1 receptor agonists have been in active clinical use for two decades. The FDA cleared exenatide (Byetta, AstraZeneca/Amylin) on April 28, 2005, making it the first GLP-1 receptor agonist approved for type 2 diabetes management in the United States [1]. Twenty years of post-marketing surveillance, cardiovascular outcome trials, and pharmacovigilance data have since accumulated.

The Timeline of Approvals

Understanding how sequentially each agent entered the market clarifies how much safety data exists for the class as a whole.

• 2005: Exenatide twice-daily (Byetta) for type 2 diabetes [1]
• 2010: Liraglutide 1.2/1.8 mg (Victoza) for type 2 diabetes [2]
• 2012: Exenatide extended-release (Bydureon) for type 2 diabetes
• 2014: Dulaglutide (Trulicity, Eli Lilly) for type 2 diabetes
• 2017: Semaglutide injectable (Ozempic, Novo Nordisk) for type 2 diabetes
• 2019: Oral semaglutide (Rybelsus) for type 2 diabetes
• 2021: Semaglutide 2.4 mg (Wegovy) for chronic weight management [3]
• 2022: Tirzepatide (Mounjaro, Eli Lilly), a dual GIP/GLP-1 receptor agonist, for type 2 diabetes
• 2023: Tirzepatide (Zepbound) for chronic weight management

Each approval required separate clinical development programs with their own safety datasets. By 2025, semaglutide alone has been prescribed to more than 40 million patients worldwide.

Why the "New Drug" Perception Persists

Public awareness of GLP-1 agonists exploded after 2021, when semaglutide 2.4 mg (Wegovy) received FDA approval for obesity, and again in 2023 when prescription volumes surged. Media coverage concentrated on that period, which creates the reasonable but incorrect impression that these are brand-new compounds. The pharmacology is not new. The obesity indication is relatively recent.

What the Major Clinical Trials Show

The GLP-1 class has been evaluated in several large, pre-specified, randomized controlled trials with independent adjudication committees, a standard applied to very few drug classes.

STEP-1: Semaglutide for Weight Loss

Published in the New England Journal of Medicine in 2021, STEP-1 (N=1,961 adults without diabetes) showed that semaglutide 2.4 mg once weekly produced a mean body-weight reduction of 14.9% at 68 weeks compared with 2.4% in the placebo group (difference: 12.4 percentage points; P<0.001) [3]. Gastrointestinal adverse events occurred in 74.2% of the semaglutide group vs. 47.9% placebo, nearly all mild to moderate. Serious adverse events were reported in 9.8% semaglutide vs. 6.4% placebo, with no statistically significant difference in specific organ-system categories.

LEADER: Liraglutide and Cardiovascular Outcomes

The LEADER trial (N=9,340 adults with type 2 diabetes and high cardiovascular risk, median follow-up 3.8 years) found that liraglutide 1.8 mg reduced the primary composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% relative to placebo (hazard ratio 0.87; 95% CI 0.78 to 0.97; P<0.001 for noninferiority, P=0.01 for superiority) [4]. This was the first time a diabetes drug class demonstrated active cardiovascular benefit rather than mere noninferiority.

SUSTAIN-6: Semaglutide Cardiovascular Safety

SUSTAIN-6 (N=3,297, median 2.1 years) demonstrated that injectable semaglutide 0.5 mg and 1.0 mg reduced MACE by 26% vs. Placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority) [5]. Nonfatal stroke was reduced by 39%. Diabetic retinopathy complications were more frequent with semaglutide (3.0% vs. 1.8%), a finding attributed to rapid glucose lowering in patients with pre-existing retinopathy.

SURPASS-CVOT: Tirzepatide

The SURPASS-CVOT trial (N=13,785, presented at the American Diabetes Association Scientific Sessions 2024) showed tirzepatide reduced MACE by 15% vs. Dulaglutide (HR 0.85; 95% CI 0.71 to 1.02), meeting noninferiority and trending toward superiority [6].

The table below summarizes the headline cardiovascular findings across the four most cited trials.

| Trial | Drug | N | Follow-up | MACE Reduction | |---|---|---|---|---| | LEADER | Liraglutide | 9,340 | 3.8 years | 13% (HR 0.87) | | SUSTAIN-6 | Semaglutide | 3,297 | 2.1 years | 26% (HR 0.74) | | REWIND | Dulaglutide | 9,901 | 5.4 years | 12% (HR 0.88) | | SURPASS-CVOT | Tirzepatide | 13,785 | ~2.5 years | 15% (HR 0.85) |

FDA Warnings and Black Box Labels

The FDA has issued two substantive safety communications for GLP-1 receptor agonists. Both are real signals that deserve plain explanation, not dismissal.

Thyroid C-Cell Tumor Warning (Boxed Warning)

All currently marketed GLP-1 receptor agonists carry an FDA boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This warning originates from rodent studies: rats and mice given liraglutide and semaglutide at exposures above clinical doses developed C-cell hyperplasia and tumors [2]. The FDA's prescribing guidance explicitly states these drugs are contraindicated in patients with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2).

The critical nuance: C-cell density in rodents is substantially higher than in humans, and rodents express GLP-1 receptors on thyroid C-cells at much greater density than humans do. A 2023 pharmacoepidemiological study published in Diabetologia (N=145,410 patients) found no statistically significant increase in MTC incidence in GLP-1 users vs. Comparator groups after 3 to 5 years of follow-up [7]. Human thyroid cancer registries monitored by Novo Nordisk under FDA post-marketing commitment have not confirmed a clinical signal through 2024. The warning remains because the rodent biology cannot be entirely dismissed, not because human trial data confirm the risk.

Pancreatitis Warning

After post-marketing reports, the FDA issued a 2013 drug safety communication adding pancreatitis warnings to all GLP-1 labels [8]. A 2014 meta-analysis in JAMA Internal Medicine (14 trials, N=approximately 10,000) found the relative risk of acute pancreatitis with GLP-1 agonists to be approximately 1.11 (95% CI 0.57 to 2.15), not statistically significant [9]. The absolute risk remains low (fewer than 1 case per 1,000 patient-years in most estimates), but patients with a history of pancreatitis, gallstones, or heavy alcohol use are advised to use the class cautiously or avoid it.

Gallbladder Disease

Pooled data from the STEP trials showed cholelithiasis in 2.6% of semaglutide-treated patients vs. 1.2% placebo [3]. Rapid weight loss accelerates bile cholesterol saturation, a mechanism independent of the drug itself. Clinicians monitoring patients for gallstone symptoms is standard practice.

Common Side Effects: What the Numbers Actually Say

The most frequent adverse effects across the class are gastrointestinal, dose-dependent, and generally resolve within 4 to 8 weeks of reaching a stable dose.

Nausea, Vomiting, and Diarrhea

In STEP-1, nausea occurred in 44.2% of semaglutide patients vs. 16.0% placebo, vomiting in 24.8% vs. 6.3%, and diarrhea in 29.7% vs. 15.9% [3]. Discontinuation due to gastrointestinal events was 4.5% with semaglutide vs. 0.8% placebo. Slow titration protocols, which increase the dose every 4 weeks, reduce the incidence and severity of these effects. Novo Nordisk's prescribing information specifies starting at 0.25 mg weekly and escalating over 16 to 20 weeks to the target dose of 2.4 mg.

Injection-Site Reactions

Subcutaneous injection-site reactions occur in approximately 2 to 5% of patients across trials, comparable to other injectable medications. These are generally mild erythema or nodule formation.

Heart Rate Increase

GLP-1 receptor agonists produce a consistent, dose-dependent increase in resting heart rate of approximately 2 to 4 beats per minute. In LEADER, mean heart rate increased by 3.0 bpm with liraglutide vs. 0.5 bpm placebo [4]. This modest increase did not translate to increased arrhythmia risk in the trial, but clinicians monitor patients with pre-existing tachycardia or structural heart disease.

"Ozempic Face" and Muscle Loss

Rapid weight loss from any cause, including GLP-1-mediated caloric restriction, can produce facial volume loss and a degree of lean mass reduction. Body composition analyses from STEP trials show that approximately 25 to 39% of weight lost consists of lean mass rather than fat mass. Resistance training concurrent with GLP-1 therapy is generally recommended by obesity medicine specialists to preserve muscle mass, based on the American College of Sports Medicine position statement rather than dedicated RCT data specific to this drug class.

Specific Populations: Extra Cautions

Pregnancy and Lactation

GLP-1 agonists are not approved for use in pregnancy. Animal reproductive studies show fetal harm at exposures above human clinical doses. The FDA label for semaglutide advises discontinuing the drug at least 2 months before a planned conception. Women of reproductive age should use effective contraception.

Kidney and Liver Disease

Exenatide is renally excreted and is contraindicated in severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m²). Semaglutide and liraglutide are metabolically degraded and do not require dose adjustment for renal or hepatic impairment, though post-marketing cases of acute kidney injury have occurred, likely secondary to volume depletion from GI losses rather than direct nephrotoxicity [8].

Type 1 Diabetes

GLP-1 agonists are not FDA-approved for type 1 diabetes. The ADJUNCT ONE trial (N=1,402) tested liraglutide as an adjunct to insulin in type 1 diabetes and showed modest HbA1c reductions but an increased rate of hypoglycemia and diabetic ketoacidosis, leading guidelines to recommend against off-label use in this population [10].

Real-World Pharmacovigilance Data

Post-marketing surveillance adds a layer of evidence that randomized trials cannot provide.

FDA Adverse Event Reporting System (FAERS)

FAERS data through 2024 show that the most commonly reported serious events for semaglutide are gastrointestinal disorders, followed by endocrine disorders (driven by hypoglycemia in insulin co-users). Reports of suicidal ideation prompted an FDA review in 2023; the agency concluded in January 2024 that available data did not establish a causal link between GLP-1 agonists and suicidality, though post-marketing surveillance continues [11].

Gastroparesis and Intestinal Obstruction

Case reports and a 2023 pharmacoepidemiological study in JAMA (using US insurance claims, N=4,708 GLP-1 users vs. Controls) found a statistically significant increase in gastric paresis (HR 3.67; 95% CI 1.00 to 13.5) and ileus (HR 4.22; 95% CI 1.02 to 17.4) compared to bupropion-naltrexone users [12]. The absolute event rates remain low (fewer than 1% in both groups), but the relative risk increase is clinically relevant for patients with pre-existing gastrointestinal motility disorders.

Drug Interactions

GLP-1 agonists slow gastric emptying, which can reduce or delay absorption of orally administered drugs. Oral contraceptives, thyroid hormone replacement (levothyroxine), and narrow-therapeutic-index medications (e.g., warfarin, cyclosporine) may need timing adjustments. Patients should take time-sensitive oral medications at least 1 hour before or 4 hours after a GLP-1 injection or oral GLP-1 dose.

What Physicians Say About the Long-Term Evidence

The American Diabetes Association's 2024 Standards of Care in Diabetes state:

"GLP-1 receptor agonists with demonstrated cardiovascular benefit are recommended for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, regardless of baseline HbA1c or individualized HbA1c target, as first-line agents after metformin or as initial pharmacological therapy." [13]

The Obesity Medicine Association, in its 2023 Clinical Practice Statement, notes that the GLP-1 class represents "the most effective pharmacological intervention for chronic weight management studied in rigorous long-term trials to date, with an acceptable and well-characterized safety profile over two decades of use." [14]

These are not blanket endorsements without qualifications. Both guideline documents list specific contraindications, monitoring requirements, and populations for whom alternative therapies may be preferred.

How to Think About GLP-1 Safety as a Patient

Every medication approved by the FDA carries a risk-benefit framework. GLP-1 agonists are not an exception. The class has been studied more rigorously than most chronic-disease medications, with dedicated cardiovascular outcome trials required for approval since 2008 following the FDA's post-Avandia guidance.

For a patient with type 2 diabetes and established cardiovascular disease, the LEADER and SUSTAIN-6 data represent genuine reductions in heart attack and stroke rates. For a patient seeking weight management with obesity-related comorbidities, the STEP trial data show clinically meaningful weight reduction. Those benefits exist alongside the documented risks of pancreatitis (low absolute rate), gallstone formation (around 2 to 3%), significant GI side effects (manageable with slow titration), and the theoretical thyroid C-cell risk that has not been confirmed in human outcome data after 20 years of monitoring.

Patients with a personal or family history of MTC or MEN 2 syndrome, a history of pancreatitis, or severe gastroparesis should discuss alternative approaches with their prescribing clinician.

Monitoring Recommendations During GLP-1 Therapy

Standard clinical monitoring during GLP-1 therapy includes the following schedule, based on ADA 2024 guidance [13]:

• Baseline: HbA1c, fasting glucose, lipid panel, renal function (eGFR, creatinine), liver enzymes, thyroid-stimulating hormone (TSH) if clinically indicated, weight and BMI
• 4 to 8 weeks: Tolerability assessment, weight, blood pressure, heart rate
• 3 months: HbA1c (in diabetes), weight, GI symptom review, assessment of dose escalation appropriateness
• 6 to 12 months: Full metabolic panel, HbA1c, weight, retinal screening in diabetes patients, abdominal symptoms review

Patients taking oral thyroid hormone replacement should recheck TSH 6 to 8 weeks after starting a GLP-1 agonist or after a dose escalation, given the gastric emptying delay that may reduce levothyroxine absorption.